Sputtr.com | Alternative Search Engine


MEDIVIR, FINANCIAL STATEMENT, 1 January - 31 December 2006

MIV-170—outlicensed to Bristol-Myers Squibb The MIV-170 project represents a new structural class in the NNRTI segment. The polymerase inhibitor MIV-170 has demonstrated excellent potency in vitro , and an enhanced resistance barrier in preclinical studies.

MEDIVIR, INTERIM REPORT 1 January - 31 March 2007

3 MIV-160 outlicensed to Guangdong Lantai Viewland Pharmaceutical Co. Ltd. The last of Medivir's polymerase inhibitors, MIV-160, was outlicensed to Guangdong Lantai Viewland Pharmaceuticals (Lantai Pharmaceutical).

Final summary to Unit Holders July 27 2010 2

... to phase 2 studies which were on “clinical hold” beginning August 2008; and c) the licensor’s interest in pexiganan, an anti-microbial topical treatment, that Genaera had advanced through two phase 3 studies in 1999 without receiving marketing approval and which Genaera had outlicensed for ...

Contact: Company:

In addition to Beijing Med-Pharm's license in China, Cytokine has outlicensed Misopess in the United States and Korea and is seeking licensing partners for Europe and other markets.

Pi Peli Ne wat Ch

Sancuso (granisetron ProStrakan chemotherapy- 5 hydroxytryptamine new licensee outlicensed to Kyowa transdermal induced nausea 3 antagonist hakko Kirin; hong Kong,

SPECIALTY PHARMA COMPANY Risk mitigated drug development

Commercialised products • Abstral® •Edluar™ • Diabact® • Heliprobe system® Outlicensed programs • OX-CLI/ESI • OX-MPI • OX17 • OX-NLA CURRENT FINANCIAL ASSETS Page 20 These projects have generated USD 130m in license revenue to date Potential future development & sales ...

Glenmark's consolidated revenue increases by 18 % to Rs ...

GRC 6211 has been outlicensed to Eli Lilly & company. In December 2008, Glenmark bagged the prestigious SCRIP award for the "Best Pharma Company in the World - SME"and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London.


Finally, if there are benefits of co-development (gains-from-trade model) and/or if only high-quality drugs are outlicensed (scenarios 2 and 3 of the signaling model), then drugs that are co-developed should be more likely to advance than those developed independently.

D PIPELINES, As of October 20, 2011

... VEGF receptor inhibitor Phase Ⅰ Cancer Oral In-house KHK2866 Anti-HB-EGF humanized antibody Phase Ⅰ in USA Cancer Injection In-house POTELLIGENT® LY2523355 Litronesib M phase kinesin Eg5 inhibitor Phase Ⅰ Cancer Injection In-house World wide outlicensed to Eli Lilly for the ...

Roger C. Wiegand

Patent estate was outlicensed. • Herpesvirus assemblin protease inhibitors were developed and outlicensed • Developed N-myristoyltransferase inhibitors as antifungal compounds through preclinical testing G.D. Searle, formerly a wholly-owned pharmaceutical subsidiary of Monsanto Co. is now part of ...